Related Experiment Videos
[Drug hypersensitive syndrome caused by fluindione].
A Sparsa1, C Bédane, H Benazahary
1Service de Dermatologie et Vénéréologie, Hôpital Dupuytren, CHRU, Limoges.
Annales De Dermatologie Et De Venereologie
|March 23, 2002
Summary
Fluindione can cause severe hypersensitivity reactions, including skin issues and organ damage. Early recognition and patch testing are crucial for diagnosis and management of these adverse drug events.
Area of Science:
- Pharmacovigilance
- Clinical Toxicology
- Dermatology
Background:
- Fluindione (Previscan) is an oral anticoagulant used for thromboembolic diseases.
- Common anticoagulant complications include bleeding.
- Severe immuno-allergic reactions, like hepatitis and renal failure, are known risks.
Observation:
- This study reports the first five cases of fluindione-induced hypersensitivity syndrome.
- Patients presented with erythroderma, lymphadenopathy, fever, eosinophilia, and elevated liver enzymes.
- Reactions occurred 3-8 weeks post-introduction, resolving after drug withdrawal, sometimes requiring steroids.
Findings:
- Fluindione hypersensitivity syndrome can manifest with severe skin and systemic symptoms.
- Patch testing with fluindione remained positive long after the acute episode.
- Multisystemic involvement, including acute hepatitis and renal failure, may occur without prominent skin manifestations.
Implications:
- Fluindione-induced hypersensitivity syndrome is a serious adverse drug reaction.
- Physicians should consider this syndrome in patients on fluindione with unexplained systemic symptoms.
- Patch testing is a valuable diagnostic tool for identifying fluindione as the causative agent.